BECAS
SOLERNÓ Luisina MarÍa
congresos y reuniones científicas
Título:
Evaluation of the antitumor activity of synthetic peptide [V4Q5]dDAVP in addition to standard chemotherapy in preclinical colorectal cancer models
Autor/es:
SOBOL NT; SOLERNÓ LM; RODRÍGUEZ RB; PIFANO M; RIPOLL GV; ALONSO DF; GARONA J
Lugar:
Mar del Plata
Reunión:
Congreso; Reunión Anual de la Sociedad Argentina de Investigación Clínica; 2018
Institución organizadora:
Sociedad Argentina de Investigación Clínica
Resumen:
Colorectal cancer (CRC) stands as a major problem for publichealth, mainly due to related mortality caused by the metastatic progression.[V4Q5]dDAVP is a second generation vasopressin analogwith reported antimetastatic activity in breast and lung cancer models,which acts as a specific vasopressin type-2 receptor (AVPR2)agonist in tumor and microvascular cells. Our aim was to explore forthe first time the potential benefits of the addition of [V4Q5]dDAVPto an established standard-of-care chemotherapy as 5- fluorouracil(5-FU), in preclinical CRC models using mouse CT-26 and humanCOLO-205 cell lines. Results were statistically analyzed by StudentT-test or ANOVA, using GraphPad Prism 6.0 and Compusyn software.In vitro, the addition of [V4Q5]dDAVP (1 μM) to the treatmentwith 5-FU (0,25-5 μM) exerted a synergic inhibitory effect on proliferationof CRC cells expressing AVPR2 (p
